Traders Purchase Large Volume of Cardiff Oncology Call Options (NASDAQ:CRDF)

Cardiff Oncology, Inc. (NASDAQ:CRDF) was the recipient of unusually large options trading on Tuesday. Traders acquired 2,705 call options on the stock. This is an increase of approximately 288% compared to the average volume of 698 call options.

Cardiff Oncology News Summary

Here are the key news stories impacting Cardiff Oncology this week:

• Positive Sentiment: Randomized Phase 2 update showed onvansertib added to FOLFIRI/bev produced dose‑dependent improvements in overall response rates and durability trends (PFS), supporting continued development in first‑line RAS‑mutated mCRC. GlobeNewswire — Phase 2 Update
• Positive Sentiment: Research coverage remains supportive: Noble Financial reiterated a Buy rating on CRDF, which can help stabilize investor sentiment after the data release. The Globe and Mail — Noble Financial
• Positive Sentiment: Unusually large call option buying was reported (2,705 calls, +288% vs. typical volume), indicating some traders placed bullish bets ahead of or after the announcements.
• Neutral Sentiment: Cardiff announced executive leadership changes as it transitions to late‑stage development and named Mani Mohindru interim CEO — a move intended to support execution but one that also introduces near‑term management transition risk. GlobeNewswire — Leadership Change
• Neutral Sentiment: Company provided a transcript/discussion of the management transition and Phase 2 data (detailed readout available), useful for investors doing deeper diligence. Seeking Alpha — Transcript
• Neutral Sentiment: Reported short‑interest data for January appears to show zero shares (likely a reporting anomaly), so no clear short‑squeeze pressure is indicated by those figures.
• Negative Sentiment: Despite the company’s positive press release, market reaction was negative—CRDF shares tumbled after the Phase 2 update, suggesting investors found the data mixed or not convincing enough for near‑term valuation upside. Investing.com — Stock Tumbles
• Negative Sentiment: Industry press noted the stock dipped as Cardiff advances its Phase 2 CRC program, reflecting investor caution despite scientific progress — market semantics and expectations appear to have driven selling. BioWorld — Market Reaction

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Cardiff Oncology in a research note on Wednesday. Finally, Noble Financial assumed coverage on Cardiff Oncology in a research report on Monday, January 5th. They set an “outperform” rating and a $12.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.13.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CRDF. Jeppson Wealth Management LLC bought a new position in Cardiff Oncology in the 3rd quarter valued at approximately $25,000. Brooklyn Investment Group bought a new stake in Cardiff Oncology during the 3rd quarter worth $26,000. Capital Advisors Wealth Management LLC bought a new stake in Cardiff Oncology during the 4th quarter worth $30,000. Integrity Alliance LLC. acquired a new position in Cardiff Oncology in the 2nd quarter worth about $41,000. Finally, Readystate Asset Management LP bought a new position in Cardiff Oncology in the third quarter valued at about $43,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Stock Performance

Shares of Cardiff Oncology stock opened at $1.62 on Thursday. The firm has a 50-day moving average of $2.60 and a 200-day moving average of $2.51. Cardiff Oncology has a 52-week low of $1.62 and a 52-week high of $4.99. The stock has a market cap of $109.12 million, a PE ratio of -2.05 and a beta of 1.40.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. Cardiff Oncology had a negative net margin of 10,064.27% and a negative return on equity of 77.21%. The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.12 million. Equities research analysts predict that Cardiff Oncology will post -0.99 earnings per share for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.